Abstract
Neglected tropical diseases (NTDs) are a group of approximately 20 diseases that affect part of the population in Sub- and Tropical countries. In the past, pharmaceutical industries and governmental agencies have invested in the control, elimination and eradication of such diseases. Among these diseases, Chagas disease (CD) and Human African trypanosomiasis (HAT) are a public health problem, mainly in the countries from the American continent and sub-Saharan African. In this context, the search for new therapeutic alternatives against such diseases has been growing in recent years, presenting cysteine proteases as the main strategy to discover new anti-trypanosomal drugs. Thus, cruzain and rhodesain enzymes are targets widely studied, since the cruzain is present in all stages of the parasite's life, related to the stages of proliferation and differentiation and infection of macrophages; while the rhodesain is related to the immune defense process. In addition, knowledge about the amino acid sequences and availability of X-ray complexes have stimulated the drug searching against these targets, mainly through molecular modeling studies. Thus, this review manuscript will be addressed to cruzain and rhodesain inhibitors developed in the last 10 years, which could provide basis for new lead compounds in the discovery of new trypanocidal drugs. We found 117 studies involving inhibitors of cruzain and rhodesain, being thiosemicarbazones, semicarbazones, N-acylhydrazones, thiazoles-hydrazone, thiazolidinones-hydrazones, oxadiazoles, triazoles, triazines, imidazoles, peptidomimetic, and others. All references were obtained using “cruzain” or “rhodesain” and “inhibitor” as keywords in Science Direct, Bentham Science, PubMed, Espacenet, Springer, ACS Publisher, Wiley, Taylor and Francis, and MDPI (Multidisciplinary Digital Publishing Institute) databases. Finally, we highlighted all these chemical classes of molecules to provide valuable information that could be used to design new inhibitors against Chagas disease and sleeping sickness in the future.
Keywords: Chagas disease, Human African trypanosomiasis, Cruzain, Rhodesain, Drug discovery, Molecular modeling.
Current Topics in Medicinal Chemistry
Title:Cruzain and Rhodesain Inhibitors: Last Decade of Advances in Seeking for New Compounds Against American and African Trypanosomiases
Volume: 21 Issue: 21
Author(s): Igor José dos Santos Nascimento, Thiago Mendonça de Aquino and Edeildo Ferreira da Silva-Júnior*
Affiliation:
- Chemistry and Biotechnology Institute, Federal University of Alagoas, Maceio,Brazil
Keywords: Chagas disease, Human African trypanosomiasis, Cruzain, Rhodesain, Drug discovery, Molecular modeling.
Abstract: Neglected tropical diseases (NTDs) are a group of approximately 20 diseases that affect part of the population in Sub- and Tropical countries. In the past, pharmaceutical industries and governmental agencies have invested in the control, elimination and eradication of such diseases. Among these diseases, Chagas disease (CD) and Human African trypanosomiasis (HAT) are a public health problem, mainly in the countries from the American continent and sub-Saharan African. In this context, the search for new therapeutic alternatives against such diseases has been growing in recent years, presenting cysteine proteases as the main strategy to discover new anti-trypanosomal drugs. Thus, cruzain and rhodesain enzymes are targets widely studied, since the cruzain is present in all stages of the parasite's life, related to the stages of proliferation and differentiation and infection of macrophages; while the rhodesain is related to the immune defense process. In addition, knowledge about the amino acid sequences and availability of X-ray complexes have stimulated the drug searching against these targets, mainly through molecular modeling studies. Thus, this review manuscript will be addressed to cruzain and rhodesain inhibitors developed in the last 10 years, which could provide basis for new lead compounds in the discovery of new trypanocidal drugs. We found 117 studies involving inhibitors of cruzain and rhodesain, being thiosemicarbazones, semicarbazones, N-acylhydrazones, thiazoles-hydrazone, thiazolidinones-hydrazones, oxadiazoles, triazoles, triazines, imidazoles, peptidomimetic, and others. All references were obtained using “cruzain” or “rhodesain” and “inhibitor” as keywords in Science Direct, Bentham Science, PubMed, Espacenet, Springer, ACS Publisher, Wiley, Taylor and Francis, and MDPI (Multidisciplinary Digital Publishing Institute) databases. Finally, we highlighted all these chemical classes of molecules to provide valuable information that could be used to design new inhibitors against Chagas disease and sleeping sickness in the future.
Export Options
About this article
Cite this article as:
dos Santos Nascimento José Igor , de Aquino Mendonça Thiago and da Silva-Júnior Ferreira Edeildo *, Cruzain and Rhodesain Inhibitors: Last Decade of Advances in Seeking for New Compounds Against American and African Trypanosomiases, Current Topics in Medicinal Chemistry 2021; 21 (21) . https://dx.doi.org/10.2174/1568026621666210331152702
DOI https://dx.doi.org/10.2174/1568026621666210331152702 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Functional Chemical Groups that May Likely Become a Source for the Synthesis of Novel Central Nervous System (CNS) Acting Drugs
Central Nervous System Agents in Medicinal Chemistry Secoiridoid Amarogentin from ‘Gentianaceae’ with their Health Promotion, Disease Prevention and Modern Analytical Aspects
Current Bioactive Compounds SARS-CoV-2 Induced Neurological Manifestations Entangles CytokineStorm that Implicates for Therapeutic Strategies
Current Medicinal Chemistry Pediatric Phagophobia: A Systematic Review and a Case Report ofPharmacological Interventions
New Emirates Medical Journal Therapeutic Intervention of Serine Protease Inhibitors againstHepatitis C Virus
Current Medicinal Chemistry Metal Ion and Dye Adsorption Potential of Grafted Co-polymer of Polysaccharidesfor the Treatment of Wastewater
Current Applied Polymer Science Current Status of Newer Antiinfectives
Recent Patents on Anti-Infective Drug Discovery A Review of the Chemical and Pharmacological Aspects of the Genus Marrubium
Current Pharmaceutical Design Assessment of COVID-19 Treatment Advised in Different Ethnic Populations
Current Drug Safety Current and Emerging Pharmacological Therapies for Cushing's Disease
Current Pharmaceutical Design Recent Progress in the Chemotherapy of Human Fungal Diseases. Emphasis on 1,3-β-Glucan Synthase and Chitin Synthase Inhibitors
Current Medicinal Chemistry Cervicocranial Arterial Dissection: An Analysis of the Clinical Features, Prognosis, and Treatment Efficacy
Current Neurovascular Research Naturally Occurring Methyl Salicylate Glycosides
Mini-Reviews in Medicinal Chemistry Rationalizing the Study of Plants for the Treatment of Oral Pain
Current Chemical Biology Data-driven Approach to Detect and Predict Adverse Drug Reactions
Current Pharmaceutical Design Fibromyalgia and Bipolar Disorder: Emerging Epidemiological Associations and Shared Pathophysiology
Current Molecular Medicine Anderson-Fabry Disease: A Multiorgan Disease
Current Pharmaceutical Design Endogenous Repair System of Oxidative Damage of DNA
Current Chemical Biology Sigma-2 Receptor as a Potential Drug Target
Current Medicinal Chemistry Repurposing of Chemotherapeutics to Combat COVID-19
Current Topics in Medicinal Chemistry